In silico methods for predicting T-cell epitopes: Dr Jekyll or Mr Hyde?

Expert Review of Proteomics

Volumn 6, Issue 5, 2009, Pages 527-537

  Gowthaman, Uthaman ^a   Agrewala, Javed N ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

Author keywords

Epitope; HLA; In silico; Promiscuous peptide

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VACCINE;

ANTIGEN BINDING; ARTIFICIAL NEURAL NETWORK; CLASSIFICATION ALGORITHM; COMPUTER MODEL; DRUG DESIGN; HUMAN; NONHUMAN; PREDICTION; PROBABILITY; PROTEIN MOTIF; REVIEW; STATISTICAL PARAMETERS; SUPPORT VECTOR MACHINE; T LYMPHOCYTE;

ALGORITHMS; EPITOPES; HLA ANTIGENS; HUMANS; MARKOV CHAINS; NEURAL NETWORKS (COMPUTER); T-LYMPHOCYTES;

EID: 70350457586     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.09.71     Document Type: Review

References (72)

1. Fundamental Immunology. Paul WE (Ed.). Lippincott Williams and Wilkins, PA, USA (2003).
2. Kaufmann SHE. The contribution of immunology to the rational design of novel antibacterial vaccines. Nat. Rev. Microbiol. 5, 491-504 (2007).
3. Townsend ARM, Gotch FM, Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42, 457-467 (1985). • Evidence for immunodominance - the immune response is directed only against a specific portion of a whole antigen.
4. Sercarz EE, Lehmann PV, Ametani A et al. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11, 729-766 (1993). (Pubitemid 23115022)
5. Zinkernagel RM, Doherty PC. Restriction of in vitro T-cell mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248, 701-702 (1974). • Classic study demonstrating the phenomenon of MHC restriction. T cells cannot recognize antigenic peptides by itself but only when presented in context with self-MHC.
6. Davis MN, Flower DR. Harnessing bioinformatics to discover new vaccines. Drug Discov. Today 12, 389-395 (2007).
7. Robinson J, Waller MJ, Parham P et al. SGE IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. Nucl. Acids Res. 31, 311-314 (2003). (Pubitemid 36150392)
8. Babbitt B, Allen PM, Matsueda G et al. The binding of immunogenic peptides to Ia histocompatibility molecules. Nature 317, 359-361 (1985). •• Demonstrates that an antigenic peptide does not bind to all alleles. Each allelic variant recognizes a set of restricted peptides. (Pubitemid 15232524)
9. Garrett TPJ, Saper MA, Bjorkman PJ et al. Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature 342, 692-696 (1989).
10. Reche PA, Glutting JP, Zhang H, Reinherz EL. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 56, 405-419 (2004). (Pubitemid 39359226)
11. Tong JC, Tan TW, Ranganathan S. Methods and protocols for prediction of immunogenic epitopes. Brief Bioinformatics 8, 96-108 (2006). (Pubitemid 47072260)
12. Gowthaman U, Agrewala JN. In silico tools for predicting peptides binding to HLA-class II molecules: more confusion than conclusion. J. Proteome Res. 7, 154-163 (2008). •• Shows that prediction efficiencies vary greatly for different alleles of the same program. (Pubitemid 351171127)
13. Rothbard JB, Gefter ML. Interactions between immunogenic peptides and MHC proteins Annu. Rev. Immunol. 9, 527-565 (1991).
14. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Ann. Rev. Immunol. 24, 419-466 (2006).
15. Baldi P, Brunak S, Chauvin Y et al. Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics 6(5), 412-424 (2000). (Pubitemid 30487963)
16. Greenbaum JA, Andersen PH, Blythe M et al. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J. Mol. Recognit. 20(2), 75-82 (2007). (Pubitemid 46761248)
17. Sette A, Buus S, Appella E et al. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc. Natl Acad. Sci. USA 86, 3296-3300 (1989). (Pubitemid 19129598)
18. Rammensee H, Bachmann J, Emmerich NP et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219 (1999). (Pubitemid 30099526)
19. Kast WM, Brandt RM, Sidney J et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papilloma virus type 16 E6 and E7 proteins. J. Immunol. 152, 3904-3912 (1994). (Pubitemid 24111062)
20. Ruppert J, Sidney J, Celis E et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74, 929-937 (1993). (Pubitemid 23270612)
21. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152, 163-175 (1994).
22. Schönbach C, Ibe M, Shiga H et al. Fine tuning of peptide binding to HLA-B*3501 molecules by nonanchor residues. J. Immunol. 14, 5951-5985 (1995).
23. Southwood S, Sidney J, Kondo A et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160, 3363-3373 (1998). (Pubitemid 28164729)
24. Nielsen M, Lundegaard C, Worning P et al. Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach. Bioinformatics 20, 1388-1397 (2004). (Pubitemid 38937025)
25. Rajapakse M, Wyse L, Schmidt B et al. Deriving matrix of peptide-MHC interactions in diabetic mouse by genetic algorithm. Lecture Notes in Computer Sci. 3578, 440-447 (2005). (Pubitemid 41431692)
26. Donnes P, Kohlbacher O. SVMHC: a server for prediction of MHC-binding peptides. Nucl. Acids Res. 34(web server issue), W194-W197 (2006). (Pubitemid 44529763)
27. Brusic V, Rudy G, Honeyman G et al. Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network. Bioinformatics 14, 121-130 (1998). (Pubitemid 28395870)
28. Yu K, Petrovsky N, Schönbach C et al. Methods for prediction of peptide binding to MHC molecules: a comparative study. Mol. Med. 8, 137-148 (2002). (Pubitemid 35015260)
29. Mamitsuka H. Predicting peptides that bind to MHC molecules using supervised learning of hidden Markov models. Proteins 33, 460-474 (1998). (Pubitemid 28565732)
30. +)-cell responses to vaccinia virus. Nat. Biotechnol. 24, 817-819 (2006). •• Also verified experimentally.
31. + T-cell epitopes. Virus Res. 132, 42-48 (2008).
32. Fonseca SG, Coutinho-Silva A, Fonseca LA et al. Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients. AIDS 20, 2263-2273 (2006). (Pubitemid 44789528)
33. Wang B, Yao K, Liu G, Xie F et al. Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes. Cell. Mol. Immunology. 6(2), 97-103 (2009).
34. Gritzapis AD, Voutsas IF, Lekka E et al. Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties. J. Immunol. 181(1), 146-154 (2008).
35. Shen L, Schroers R, Hammer J et al. Identification of a MHC class-II restricted epitope in carcinoembryonic antigen. Cancer Immunol. Immunother. 53, 391-403 (2004). (Pubitemid 38657252)
36. + T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res. 63, 8481-8486 (2003).
37. Xing Q, Pang XW, Peng JR et al. Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587. Biochem. Biophys. Res. Commun. 372, 331-335 (2008).
38. Asemissen AM, Keilholz U, Tenzer S et al. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin. Cancer Res. 12, 7476-7482 (2006). (Pubitemid 46095423)
39. Schreurs MW, Kueter EW, Scholten KB et al. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope. Cancer Immunol. Immunother. 54, 703-712 (2005).
40. Maecker B, von Bergwelt-Baildon MS, Sherr DH et al. Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int. J. Cancer 115, 333-336 (2005). (Pubitemid 40586746)
41. Koren E, De Groot AS, Jawa V et al. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin. Immunol. 124, 26-32 (2007).
42. + T cells specific for a potential HLA-A*0201 epitope from Chlamydophila pneumoniae are present in the PBMCs from infected patients. Int. Immunol. 17, 591-597 (2005).
43. + T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J. Gen. Virol. 85, 2365-2374 (2004).
44. Ouyang Q, Standifer NE, Qin H et al. Recognition of HLA class I-restricted β cell epitopes in Type 1 diabetes. Diabetes 55, 3068-3074 (2006). (Pubitemid 44923644)
45. Standifer NE, Ouyang Q, Panagiotopoulos C et al. Identification of novel HLA-A*0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives. Diabetes 55, 3061-3067 (2006). (Pubitemid 44923643)
46. + T cell epitopes from vaccinia virus induced by vaccination or infection. PLoS Pathog. 3, E144 (2007).
47. Larsen MV, Lundegaard C, Lamberth K et al. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics 8, 424 (2007).
48. Gomez-Nunez M, Pinilla-Ibarz J, Dao T et al. Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leukemia Res. 30, 1293-1298 (2006). (Pubitemid 44223735)
49. Al-Attiyah R, Mustafa AS. Computer-assisted prediction of HLA-DR binding and experimental analysis for human promiscuous Th1-cell peptides in the 24 kDa secreted lipoprotein (LppX) of Mycobacterium tuberculosis. Scand. J. Immunol. 59, 16-24 (2004).
50. Stober CB, Lange UG, Roberts MT et al. From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine leishmania major infection. Vaccine 24, 2602-2616 (2006).
51. Drouin EE, Glickstein L, Kwok WW et al. Searching for borrelial T cell epitopes associated with antibiotic-refractory Lyme arthritis. Mol. Immunol. 45, 2323-2332 (2008).
52. Nyárády Z, Czömpöly T, Bosze S et al. Validation of in silico prediction by in vitro immunoserological results of fine epitope mapping on citrate synthase specific autoantibodies. Mol. Immunol. 43, 830-838 (2006).
53. Andersen MH, Tan L, Søndergaard I et al. Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens 55, 519-531 (2000). (Pubitemid 30386454)
54. Pelte C, Cherepnev G, Wang Y et al. Random screening of proteins for HLA-A*0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell epitopes recognized in the context of HLA-A*0201. J. Immunol. 172, 6783-6789 (2004). (Pubitemid 38669116)
55. Neumann F, Wagner C, Stevanovic S et al. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. Int. J. Cancer 112, 661-668 (2004). (Pubitemid 39425947)
56. Mustafa AS, Shaban FA. ProPred analysis and experimental evaluation of promiscuous T-cell epitopes of three major secreted antigens of Mycobacterium tuberculosis. Tuberculosis 86, 115-124 (2006).
57. Crowe SR, Miller SC, Brown DM et al. Uneven distribution of MHC class II epitopes within the influenza virus. Vaccine 24, 457-467 (2006).
58. Lee S, Miller SA, Wright DW et al. Tissue-specific regulation of CD8-Tlymphocyte immunodominance in respiratory syncytial virus infection. J. Virol. 81, 2349-2358 (2007). (Pubitemid 46303352)
59. Trost B, Bickis M, Kusalik A. Strength in numbers: achieving greater accuracy in MHC-I binding prediction by combining the results from multiple prediction tools. Immunome Res. 3, 5 (2007). (Pubitemid 46986269)
60. Doolan DL, Southwood S, Freilich DA et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc. Natl Acad. Sci. USA 100, 9952-9957 (2003). (Pubitemid 37087049)
61. Lin HH, Zhang GL, Tongchusak S et al. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics 12, (9 Suppl. 12), S22 (2008).
62. Hennecke J, Wiley DC. T cell receptor-MHC interactions up close. Cell 104, 1-4 (2001).
63. Stern LJ, Brown JH, Jardetzky TS et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368, 215-221 (1994).
64. Sturniolo T, Bono E, Ding J et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat. Biotechnol. 17, 555-561 (1999). (Pubitemid 29262918)
65. El-Manzalawy Y, Dobbs D, Honavar V. On evaluating MHC-II binding peptide prediction methods. PLoS ONE 24, 3(9) E3268 (2008).
66. Suri A, Lovitch SB, Unanue ER. The wide diversity and complexity of peptides bound to class II MHC molecules. Curr. Opin. Immunol. 18(1), 70-77 (2006). (Pubitemid 43049651)
67. Lin HH, Ray S, Tongchusak S et al. Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol. 9, 8 (2008). (Pubitemid 351583869)
68. MacNamara A, Kadolsky U, Bangham CRM, Asquith B. T-cell epitope prediction: rescaling can mask biological variation between MHC molecules. PLoS Comput. Biol. 5(3), E1000327 (2009).
69. + T lymphocytes specific for an epitope of the 16-kDa α-crystallin antigen of Mycobacterium tuberculosi. Eur. J. Immunol. 29, 1753-1761 (1999).
70. Agrewala JN, Wilkinson RJ. Differential regulation of Th1 and Th2 cells by p91-110 and p21-40 peptides of the 16-kD α-crystallin antigen of Mycobacterium tuberculosis. Clin. Exp. Immunol. 114(3), 392-397 (1998).
71. Halling-Brown M, Sansom CE, Davies M et al. Are bacterial vaccine antigens T-cell epitope depleted? Trends Immunol. 29(8), 374-379 (2008).
72. IMGT Database www.ebi.ac.uk/imgt/hla/stats.html